Who is sponsoring NCT02114242?

NCT02114242 is sponsored by University Hospital, Bordeaux.

What drugs are being tested in NCT02114242?

Interventions in NCT02114242: CSF, blood and urine sampling, clinical measures of disease severity and progression.

What condition does NCT02114242 study?

NCT02114242 studies Parkinsonian Syndromes, Parkinson's Disease, Multiple System Atrophy, Progressive Supranuclear Palsy.

Is NCT02114242 still recruiting?

NCT02114242 is currently status unknown. Last updated 31 March 2022.

Last reviewed 2022-03-31 · How we verify

NCT02114242: BIOPARK

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Biomarkers in Parkinsonian Syndromes

Status unknown Last updated 31 March 2022

What this trial tests

trial testing CSF, blood and urine sampling in Parkinsonian Syndromes in 100 participants. Status unknown.

Timeline

16 December 2013

Primary endpoint
16 December 2023

16 December 2025

Quick facts

Lead sponsor	University Hospital, Bordeaux
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	100
Start date	16 December 2013
Primary completion	16 December 2023
Estimated completion	16 December 2025
Sites	3 locations across France

Drugs / interventions tested

CSF, blood and urine sampling
clinical measures of disease severity and progression

Conditions studied

Parkinsonian Syndromes — all drugs for Parkinsonian Syndromes →
Parkinson's Disease — all drugs for Parkinson's Disease →
Multiple System Atrophy — all drugs for Multiple System Atrophy →
Progressive Supranuclear Palsy — all drugs for Progressive Supranuclear Palsy →

Sponsor

University Hospital, Bordeaux

Who can join

18 and older, any sex, with Parkinsonian Syndromes or Parkinson's Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Parkinson disease (PD), multiple system atrophy (MSA) and progressive supranuclear palsy (PSP) are neurodegenerative disorders. PD and MSA are alpha-synucleinopathies, which are characterized by the abnormal accumulation of alpha-synuclein, while tau protein accumulates in PSP. The development of biological markers for the diagnosis and prognosis in PD, MSA and PSP remains an unmet need. Such biological markers are crucial for future disease-modification and neuroprotection trials. Alpha-synuclein has a high potential for biomarker development since it constitutes the pathological hallmark feature in PD and MSA. The oligomeric alpha-synuclein seems to be particularly involved in abnormal protein aggregation in alpha-synucleinopathies. The main objective is to compare oligomeric alpha-synuclein CSF levels between PD, MSA and PSP patients. PD and MSA patients will receive Cerebrospinal Fluid (CSF) and blood sampling at two study visits (baseline and after 12 months). Major secondary objectives are (i) to assess potential associations between the biomarker and clinical measures of disease severity and progression in MSA and PSP, and (ii) to assess the variation of the biomarker and its correlation to disease severity and progression in PD, MSA and PSP.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Diagnostic value of cerebrospinal fluid alpha-synuclein seed quantification in synucleinopathies.
Poggiolini I, Gupta V, Lawton M, Lee S, et al · · 2022 · cited 161× · PMID 34894214 · DOI 10.1093/brain/awab431
"Janus-Faced" α-Synuclein: Role in Parkinson's Disease.
Ray B, Mahalakshmi AM, Tuladhar S, Bhat A, et al · · 2021 · cited 7× · PMID 34124057 · DOI 10.3389/fcell.2021.673395

Verify or expand the search:

Other University Hospital, Bordeaux trials

Trials by the same sponsor.

NCT07506928 — NEURO - Prognostication Using Late Somatosensory Evoked - Potentials · NA · not yet recruiting
NCT07524036 — Impact of a Nursing Educational Consultation on the Patient's Adherence to Their Post-stroke Care Plan. · NA · not yet recruiting
NCT07527494 — Digital MEDIcal TWIN for the Prediction of Arrhythmic Sudden Cardiac Death After a Myocardial Infarction · NA · not yet recruiting
NCT07527442 — Efficacy and Safety of Circumcision Alone on Risk of Febrile Urinary Tract Infections in Boys With Posterior Urethral Va · Phase 2 · not yet recruiting
NCT07478523 — FAPI-PET Value for the Initial Screening of Pancreatic and Biliary Cancers · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02114242 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University Hospital, Bordeaux
Last refreshed: 31 March 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02114242.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing